Little Green Pharma Ltd engages in the research and development, cultivation, production, manufacturing, and distribution of medicinal cannabis products in Australia and internationally. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Little Green Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LGP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: LGP's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: LGP exceeded the Australian Pharmaceuticals industry which returned -4.2% over the past year.
Return vs Market: LGP exceeded the Australian Market which returned 35.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Little Green Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StInvestors Who Bought Little Green Pharma (ASX:LGP) Shares A Year Ago Are Now Up 145%
3 months ago | Simply Wall StWhat Type Of Shareholders Make Up Little Green Pharma Ltd's (ASX:LGP) Share Registry?
11 months ago | Simply Wall StCould Little Green Pharma Ltd's (ASX:LGP) Investor Composition Influence The Stock Price?
Is Little Green Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LGP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LGP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LGP is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: LGP is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LGP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LGP is overvalued based on its PB Ratio (5.8x) compared to the AU Pharmaceuticals industry average (3.1x).
How is Little Green Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Little Green Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Little Green Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LGP is currently unprofitable.
Growing Profit Margin: LGP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LGP is unprofitable, and losses have increased over the past 5 years at a rate of 28.8% per year.
Accelerating Growth: Unable to compare LGP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LGP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.5%).
Return on Equity
High ROE: LGP has a negative Return on Equity (-22.24%), as it is currently unprofitable.
How is Little Green Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: LGP's short term assets (A$8.0M) exceed its short term liabilities (A$2.2M).
Long Term Liabilities: LGP's short term assets (A$8.0M) exceed its long term liabilities (A$1.4M).
Debt to Equity History and Analysis
Debt Level: LGP is debt free.
Reducing Debt: LGP had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LGP has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: LGP is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.
What is Little Green Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LGP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LGP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LGP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LGP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LGP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Ms. Fleta Jennifer Solomon serves as Managing Director at Little Green Pharma Ltd. She serves as Director of Little Green Pharma Ltd since May 29, 2017. She joins Little Green Pharma Ltd in February 2017. ...
CEO Compensation Analysis
Compensation vs Market: Fleta's total compensation ($USD481.34K) is above average for companies of similar size in the Australian market ($USD289.57K).
Compensation vs Earnings: Fleta's compensation has increased whilst the company is unprofitable.
Experienced Board: LGP's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.3%.
Little Green Pharma Ltd's company bio, employee growth, exchange listings and data sources
- Name: Little Green Pharma Ltd
- Ticker: LGP
- Exchange: ASX
- Founded: 2016
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$127.347m
- Shares outstanding: 187.27m
- Website: https://www.littlegreenpharma.com
- Little Green Pharma Ltd
- Level 2
- Suite 2
- West Perth
- Western Australia
Little Green Pharma Ltd engages in the research and development, cultivation, production, manufacturing, and distribution of medicinal cannabis products in Australia and internationally. It offers a range ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/13 08:20|
|End of Day Share Price||2021/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.